FDA Oncology Therapeutics Office Planned; Drug, Biologics Units To Be Merged

The agency is understood to be finalizing a plan that would complete the integration of the oncology review teams as originally intended under the CDER/CBER consolidation. Oncology Drug Products Division Director Richard Pazdur, MD, and ODE VI Director Karen Weiss, MD, are potential candidates to head the merged cancer office.